30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Principia Biopharma Inc (PRNB)

Track

Stock chart
Ticker: PRNB Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Hardiman Roy C.
Chief Business Officer
1 sale — total 499,918 USD
Planned sale 18 Sep 2020
Value US$1,683,529.93 | Price 307.03 | Shares 70,440
Planned sale 18 Aug 2020
Value US$1,063,724.80 | Price 11.76 | Shares 52,104
Planned sale 18 Aug 2020
Value US$1,500,000.00 | Price 100.00 | Shares 15,000
Planned sale 10 Aug 2020
Value US$9,334.00 | Price 93.34 | Shares 100
Planned sale 10 Aug 2020
Value US$100,815.92 | Price 90.99 | Shares 1,108
Planned sale 10 Aug 2020
Value US$62,772.99 | Price 89.68 | Shares 700
Planned sale 10 Aug 2020
Value US$224,012.19 | Price 88.40 | Shares 2,534
Planned sale 10 Aug 2020
Value US$60,844.00 | Price 86.92 | Shares 700
Planned sale 10 Aug 2020
Value US$73,886.07 | Price 86.11 | Shares 858
Planned sale 15 Jul 2020
Value US$1,201,069.50 | Price 80.07 | Shares 15,000
Planned sale 1 Jul 2020
Value US$450,000.00 | Price 60.00 | Shares 7,500
Planned sale 23 Jun 2020
Value US$156,077.76 | Price 62.38 | Shares 2,502
Planned sale 23 Jun 2020
Value US$740,744.72 | Price 61.82 | Shares 11,983
Planned sale 23 Jun 2020
Value US$31,066.09 | Price 60.32 | Shares 515
Planned sale 15 Jun 2020
Value US$6,136.80 | Price 61.37 | Shares 100
Planned sale 15 Jun 2020
Value US$304,290.74 | Price 60.81 | Shares 5,004
Planned sale 15 Jun 2020
Value US$23,957.00 | Price 59.89 | Shares 400
Planned sale 12 Jun 2020
Value US$53,617.24 | Price 62.13 | Shares 863
Planned sale 12 Jun 2020
Value US$156,630.16 | Price 61.62 | Shares 2,542
Planned sale 12 Jun 2020
Value US$95,540.98 | Price 59.90 | Shares 1,595
Planned sale 19 May 2020
Value US$488,268.00 | Price 65.10 | Shares 7,500
Planned sale 7 May 2020
Value US$164,207.21 | Price 60.39 | Shares 2,719
Planned sale 7 May 2020
Value US$196,734.01 | Price 59.96 | Shares 3,281
Planned sale 5 May 2020
Value US$399,600.00 | Price 60.00 | Shares 6,660
Planned sale 1 May 2020
Value US$50,456.70 | Price 60.07 | Shares 840
Planned sale 16 Mar 2020
Value US$173,838.38 | Price 46.36 | Shares 3,750
Planned sale 16 Mar 2020
Value US$80,192.18 | Price 45.72 | Shares 1,754
Planned sale 13 Mar 2020
Value US$5,104.00 | Price 51.04 | Shares 100
Planned sale 13 Mar 2020
Value US$58,407.65 | Price 49.46 | Shares 1,181
Planned sale 13 Mar 2020
Value US$179,304.15 | Price 48.21 | Shares 3,719
Planned sale 3 Mar 2020
Value US$19,448.01 | Price 64.83 | Shares 300
Planned sale 3 Mar 2020
Value US$348,180.34 | Price 64.10 | Shares 5,432
Planned sale 3 Mar 2020
Value US$454,251.48 | Price 63.24 | Shares 7,183
Planned sale 3 Mar 2020
Value US$130,203.25 | Price 62.45 | Shares 2,085
Planned sale 18 Feb 2020
Value US$5,207.66 | Price 68.52 | Shares 76
Planned sale 18 Feb 2020
Value US$152,611.65 | Price 68.13 | Shares 2,240
Planned sale 18 Feb 2020
Value US$40,582.19 | Price 67.08 | Shares 605
Planned sale 18 Feb 2020
Value US$89,021.02 | Price 65.94 | Shares 1,350
Planned sale 18 Feb 2020
Value US$35,374.59 | Price 64.91 | Shares 545
Planned sale 18 Feb 2020
Value US$171,388.97 | Price 63.86 | Shares 2,684
Planned sale 10 Feb 2020
Value US$369,778.76 | Price 71.11 | Shares 5,200
Planned sale 10 Feb 2020
Value US$55,621.52 | Price 69.53 | Shares 800
Sale 19 Dec 2019
Value US$29,700.00 | Price 60.00 | Shares 495
Planned sale 18 Dec 2019
Value US$70,292.47 | Price 54.28 | Shares 1,295
Planned sale 18 Dec 2019
Value US$118,392.18 | Price 53.69 | Shares 2,205
Planned sale 18 Dec 2019
Value US$52,774.70 | Price 52.77 | Shares 1,000
Planned sale 17 Dec 2019
Value US$55,115.97 | Price 54.36 | Shares 1,014
Planned sale 17 Dec 2019
Value US$359,313.66 | Price 53.94 | Shares 6,661
Planned sale 17 Dec 2019
Value US$607,063.79 | Price 52.86 | Shares 11,485
Planned sale 17 Dec 2019
Value US$302,502.07 | Price 51.80 | Shares 5,840
Planned sale 16 Dec 2019
Value US$64,825.02 | Price 49.87 | Shares 1,300
Planned sale 16 Dec 2019
Value US$207,265.71 | Price 49.29 | Shares 4,205
Planned sale 13 Dec 2019
Value US$80,681.89 | Price 49.83 | Shares 1,619
Planned sale 13 Dec 2019
Value US$166,351.96 | Price 49.20 | Shares 3,381
Buy 20 Nov 2019
Value US$1,646,700.00 | Price 29.94 | Shares 55,000
Planned sale 7 Nov 2019
Value US$323,914.00 | Price 32.39 | Shares 10,000
Buy 29 Oct 2019
Value US$312,477.32 | Price 33.98 | Shares 9,196
Buy 28 Oct 2019
Value US$2,285,548.65 | Price 33.41 | Shares 68,404
Buy 18 Oct 2019
Value US$9,999,976.00 | Price 28.00 | Shares 357,142
Buy 18 Oct 2019
Value US$14,980,000.00 | Price 28.00 | Shares 535,000
Buy 18 Oct 2019
Value US$9,999,976.00 | Price 28.00 | Shares 357,142
Sale 13 Aug 2019
Value US$1,749,685.00 | Price 35.00 | Shares 49,991
Sale 13 Aug 2019
Value US$8,750,315.00 | Price 35.00 | Shares 250,009
Sale 21 May 2019
Value US$30,250,000.00 | Price 30.25 | Shares 1,000,000
Buy 18 Sep 2018
Value US$4,590,000.00 | Price 17.00 | Shares 270,000
Buy 18 Sep 2018
Value US$4,590,000.00 | Price 17.00 | Shares 270,000
Buy 18 Sep 2018
Value US$2,975,000.00 | Price 17.00 | Shares 175,000
Buy 18 Sep 2018
Value US$4,590,000.00 | Price 17.00 | Shares 270,000
Buy 18 Sep 2018
Value US$4,250,000.00 | Price 17.00 | Shares 250,000
Buy 18 Sep 2018
Value US$4,590,000.00 | Price 17.00 | Shares 270,000
Buy 18 Sep 2018
Value US$4,590,000.00 | Price 17.00 | Shares 270,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2020-09-22 2020-09-18 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
70,440 +9.8%
307.03
US$1,683,530 		70,440 +9.8% 307.03 US$1,683,530
2020-08-20 2020-08-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
52,104 -10.1%
11.76
US$1,063,725 		52,104 -10.1% 11.76 US$1,063,725
2020-08-20 2020-08-18 PlS Planned sale
Thomas Dolca

Chief Medical Officer

Officer
57,155 -16.2%
220.60
US$4,864,688 		57,155 -16.2% 220.60 US$4,864,688
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
100 -0.3%
93.34
US$9,334 		100 -0.3% 93.34 US$9,334
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
1,108 -3.4%
90.99
US$100,816 		1,108 -3.4% 90.99 US$100,816
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
700 -2.1%
89.68
US$62,773 		700 -2.1% 89.68 US$62,773
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
2,534 -7.0%
88.40
US$224,012 		2,534 -7.0% 88.40 US$224,012
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
700 -1.9%
86.92
US$60,844 		700 -1.9% 86.92 US$60,844
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
858 -2.3%
86.11
US$73,886 		858 -2.3% 86.11 US$73,886
2020-07-17 2020-07-15 PlS Planned sale
Thomas Dolca

Chief Medical Officer

Officer
15,000 -89.1%
80.07
US$1,201,070 		15,000 -89.1% 80.07 US$1,201,070
2020-07-02 2020-07-01 PlS Planned sale
0.8
Colowick Alan
Non-Executive Director
7,500 -100.0%
60.00
US$450,000 		7,500 -100.0% 60.00 US$450,000
2020-06-25 2020-06-23 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
2,502 -75.5%
62.38
US$156,078 		2,502 -75.5% 62.38 US$156,078
2020-06-25 2020-06-23 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
11,983 -78.3%
61.82
US$740,745 		11,983 -78.3% 61.82 US$740,745
2020-06-25 2020-06-23 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
515 -3.3%
60.32
US$31,066 		515 -3.3% 60.32 US$31,066
2020-06-17 2020-06-15 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
100 -0.5%
61.37
US$6,137 		100 -0.5% 61.37 US$6,137
2020-06-17 2020-06-15 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
5,004 -20.7%
60.81
US$304,291 		5,004 -20.7% 60.81 US$304,291
2020-06-17 2020-06-15 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
400 -1.6%
59.89
US$23,957 		400 -1.6% 59.89 US$23,957
2020-06-15 2020-06-12 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
863 -0.7%
62.13
US$53,617 		863 -0.7% 62.13 US$53,617
2020-06-15 2020-06-12 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
2,542 -2.1%
61.62
US$156,630 		2,542 -2.1% 61.62 US$156,630
2020-06-15 2020-06-12 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
1,595 -1.3%
59.90
US$95,541 		1,595 -1.3% 59.90 US$95,541
2020-05-21 2020-05-19 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
7,500 -67.9%
65.10
US$488,268 		7,500 -67.9% 65.10 US$488,268
2020-05-08 2020-05-07 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
2,719 -8.1%
60.39
US$164,207 		2,719 -8.1% 60.39 US$164,207
2020-05-08 2020-05-07 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
3,281 -8.9%
59.96
US$196,734 		3,281 -8.9% 59.96 US$196,734
2020-05-05 2020-05-05 PlS Planned sale
0.8
Colowick Alan
Non-Executive Director
6,660 -100.0%
60.00
US$399,600 		6,660 -100.0% 60.00 US$399,600
2020-05-05 2020-05-01 PlS Planned sale
0.8
Colowick Alan
Non-Executive Director
840 -100.0%
60.07
US$50,457 		840 -100.0% 60.07 US$50,457
2020-03-18 2020-03-16 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
3,750 -9.5%
46.36
US$173,838 		3,750 -9.5% 46.36 US$173,838
2020-03-18 2020-03-16 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
1,754 -4.3%
45.72
US$80,192 		1,754 -4.3% 45.72 US$80,192
2020-03-17 2020-03-13 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
100 -0.1%
51.04
US$5,104 		100 -0.1% 51.04 US$5,104
2020-03-17 2020-03-13 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
1,181 -1.0%
49.46
US$58,408 		1,181 -1.0% 49.46 US$58,408
2020-03-17 2020-03-13 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
3,719 -3.1%
48.21
US$179,304 		3,719 -3.1% 48.21 US$179,304
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
300 -0.8%
64.83
US$19,448 		300 -0.8% 64.83 US$19,448
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
5,432 -12.1%
64.10
US$348,180 		5,432 -12.1% 64.10 US$348,180
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
7,183 -13.8%
63.24
US$454,251 		7,183 -13.8% 63.24 US$454,251
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
2,085 -3.8%
62.45
US$130,203 		2,085 -3.8% 62.45 US$130,203
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
76 -1.6%
68.52
US$5,208 		76 -1.6% 68.52 US$5,208
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
2,240 -31.6%
68.13
US$152,612 		2,240 -31.6% 68.13 US$152,612
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
605 -7.9%
67.08
US$40,582 		605 -7.9% 67.08 US$40,582
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
1,350 -14.9%
65.94
US$89,021 		1,350 -14.9% 65.94 US$89,021
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
545 -5.7%
64.91
US$35,375 		545 -5.7% 64.91 US$35,375
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
2,684 -21.9%
63.86
US$171,389 		2,684 -21.9% 63.86 US$171,389
2020-02-12 2020-02-10 PlS Planned sale
Goldstein David

Chief Scientific Officer

Officer
5,200 -14.4%
71.11
US$369,779 		5,200 -14.4% 71.11 US$369,779
2020-02-12 2020-02-10 PlS Planned sale
Goldstein David

Chief Scientific Officer

Officer
800 -2.2%
69.53
US$55,622 		800 -2.2% 69.53 US$55,622
2019-12-20 2019-12-19 S Sale Thomas Dolca

Chief Medical Officer

Officer
495 -50.1%
60.00
US$29,700 		495 -50.1% 60.00 US$29,700
2019-12-19 2019-12-18 PlS Planned sale Babler Martin

President, CEO

Executive Director
1,295 -7.6%
54.28
US$70,292 		1,295 -7.6% 54.28 US$70,292
2019-12-19 2019-12-18 PlS Planned sale Babler Martin

President, CEO

Executive Director
2,205 -11.5%
53.69
US$118,392 		2,205 -11.5% 53.69 US$118,392
2019-12-19 2019-12-18 PlS Planned sale Babler Martin

President, CEO

Executive Director
1,000 -5.0%
52.77
US$52,775 		1,000 -5.0% 52.77 US$52,775
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
1,014 -1.8%
54.36
US$55,116 		1,014 -1.8% 54.36 US$55,116
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
6,661 -10.8%
53.94
US$359,314 		6,661 -10.8% 53.94 US$359,314
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
11,485 -15.7%
52.86
US$607,064 		11,485 -15.7% 52.86 US$607,064
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
5,840 -7.4%
51.80
US$302,502 		5,840 -7.4% 51.80 US$302,502
2019-12-18 2019-12-16 PlS Planned sale Wolff Stefani

Chief Development Officer

Officer
1,300 -3.5%
49.87
US$64,825 		1,300 -3.5% 49.87 US$64,825
2019-12-18 2019-12-16 PlS Planned sale Wolff Stefani

Chief Development Officer

Officer
4,205 -10.2%
49.29
US$207,266 		4,205 -10.2% 49.29 US$207,266
2019-12-13 2019-12-13 PlS Planned sale Hardiman Roy C.

Chief Business Officer

Officer
1,619 -1.3%
49.83
US$80,682 		1,619 -1.3% 49.83 US$80,682
2019-12-13 2019-12-13 PlS Planned sale Hardiman Roy C.

Chief Business Officer

Officer
3,381 -2.7%
49.20
US$166,352 		3,381 -2.7% 49.20 US$166,352
2019-11-22 2019-11-20 B Purchase Becker Daniel J. Non-Executive Director
55,000 +9.0%
29.94
US$1,646,700 		55,000 +9.0% 29.94 US$1,646,700
2019-11-08 2019-11-07 PlS Planned sale Goldstein David

Chief Scientific Officer

Officer
10,000 -25.1%
32.39
US$323,914 		10,000 -25.1% 32.39 US$323,914
2019-10-30 2019-10-29 B Purchase
3.2
Becker Daniel J.
9,196 +1.5%
33.98
US$312,477 		9,196 +1.5% 33.98 US$312,477
2019-10-30 2019-10-28 B Purchase
3.2
Becker Daniel J.
68,404 +12.8%
33.41
US$2,285,549 		68,404 +12.8% 33.41 US$2,285,549
2019-10-22 2019-10-18 B Purchase
2.3
GLAXOSMITHKLINE PLC
357,142 +13.6%
28.00
US$9,999,976 		357,142 +13.6% 28.00 US$9,999,976
2019-10-22 2019-10-18 B Purchase
3.2
Becker Daniel J.
535,000 +inf%
28.00
US$14,980,000 		535,000 +inf% 28.00 US$14,980,000
2019-10-22 2019-10-18 B Purchase
3.1
George Simeon
357,142 +13.6%
28.00
US$9,999,976 		357,142 +13.6% 28.00 US$9,999,976
2019-08-15 2019-08-13 S Sale New Leaf Ventures II, L.P. Large shareholder
49,991 -11.4%
35.00
US$1,749,685 		49,991 -11.4% 35.00 US$1,749,685
2019-08-15 2019-08-13 S Sale New Leaf Ventures II, L.P. Large shareholder
250,009 -11.4%
35.00
US$8,750,315 		250,009 -11.4% 35.00 US$8,750,315
2019-05-22 2019-05-21 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,000,000 -38.4%
30.25
US$30,250,000 		1,000,000 -38.4% 30.25 US$30,250,000
2018-09-20 2018-09-18 B Purchase GLAXOSMITHKLINE PLC Large shareholder
270,000 +11.5%
17.00
US$4,590,000 		270,000 +11.5% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase Becker Daniel J. Non-Executive Director Large shareholder
270,000 +161.2%
17.00
US$4,590,000 		270,000 +161.2% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase AKKARAJU SRINIVAS Non-Executive Director
175,000 +83.9%
17.00
US$2,975,000 		175,000 +83.9% 17.00 US$2,975,000
2018-09-20 2018-09-18 B Purchase Sofinnova Venture Partners VIII, L.P. Large shareholder
270,000 +15.3%
17.00
US$4,590,000 		270,000 +15.3% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase ORBIMED ADVISORS LLC Large shareholder
250,000 +10.6%
17.00
US$4,250,000 		250,000 +10.6% 17.00 US$4,250,000
2018-09-20 2018-09-18 B Purchase New Leaf Ventures II, L.P. Large shareholder
270,000 +161.2%
17.00
US$4,590,000 		270,000 +161.2% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase George Simeon Non-Executive Director Large shareholder
270,000 +11.5%
17.00
US$4,590,000 		270,000 +11.5% 17.00 US$4,590,000
Explore more

More insider trading research around Principia Biopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America